PEARLY.

Study name	Carboplatin in EARLY triple negative breast cancer trial (PEARLY Trial)
Methods	Accrual: recruiting Accrual target: 840 Multicentre, phase 3 RCT Trial is being conducted in South Korea Blinding: open‐label study
Participants	People with stage II/III operable triple‐negative breast cancer Adjuvant or neoadjuvant: both
Interventions	Arm 1: intervention: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by taxane (docetaxel 75 mg/m2 every 3 weeks or paclitaxel 80 mg/m2 weekly for 12 doses) plus carboplatin AUC5 every 3 weeks for 4 cycles
Outcomes	Primary 5‐year event‐free survival Secondary Overall survival Distant recurrence‐free survival Locoregional recurrence‐free survival Pathological complete rate
Starting date	Planned start date: December 2015 Estimated completion date: March 2023
Contact information	Contact: Joo Hyuk Sohn, Yonsei University
Notes	Trial registration link: clinicaltrials.gov/ct2/show/NCT02441933 Trial sponsor: Yonsei University Funding considerations: not specified in trial record

AUC: area under the curve; RCT: randomised controlled trial.